Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kaushal, Deepak ^a,b   Foreman, Taylor W ^a,b   Gautam, Uma S ^a   Alvarez, Xavier ^a   Adekambi, Toidi ^c   Rangel Moreno, Javier ^d   Golden, Nadia A ^a   Johnson, Ann Marie F ^a   Phillips, Bonnie L ^a,b   Ahsan, Muhammad H ^a   Russell Lodrigue, Kasi E ^a   Doyle, Lara A ^a   Roy, Chad J ^a   Didier, Peter J ^a   Blanchard, James L ^a   Rengarajan, Jyothi ^c   Lackner, Andrew A ^a,b   Khader, Shabaana A ^e   Mehra, Smriti ^a,f  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL; CELLS AND CELL COMPONENTS; IMMUNIZATION; MEMORY; MUCUS; PRIMATE; TUBERCULOSIS; VACCINATION;

ANIMALIA; BACTERIA (MICROORGANISMS); MACACA; MYCOBACTERIUM TUBERCULOSIS;

AEROSOL; BACTERIAL PROTEIN; BCG VACCINE; SIGH PROTEIN, BACTERIA; SIGMA FACTOR;

AEROSOL; ANIMAL; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG; LUNG LAVAGE; LYMPHOID TISSUE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; PROCEDURES; RHESUS MONKEY; T LYMPHOCYTE; TUBERCULOSIS; VACCINATION;

AEROSOLS; ANIMALS; BACTERIAL PROTEINS; BCG VACCINE; BRONCHOALVEOLAR LAVAGE; IMMUNOLOGIC MEMORY; LUNG; LYMPHOID TISSUE; MACACA MULATTA; MYCOBACTERIUM TUBERCULOSIS; SIGMA FACTOR; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 84944346038     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9533     Document Type: Article

References (70)

1. Zumla, A. et al. The WHO 2014 global tuberculosis report-further to go. Lancet Glob Health 3, e10-12 (2015).
2. Kaufmann, S. H. et al. Progress in tuberculosis vaccine development and host-directed therapies - A state of the art review. Lancet Respir. Med. 2, 301-320 (2014).
3. Orme, I. M. Prospects for new vaccines against tuberculosis. Trends Microbiol. 3, 401-404 (1995).
4. Hingley-Wilson, S. M., Sambandamurthy, V. K. & Jacobs, Jr. W. R. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat. Immunol. 4, 949-955 (2003).
5. Kaufmann, S. H. et al. Progress in tuberculosis vaccine development and host-directed therapies - a state of the art review. Lancet Respir. Med. 2, 301-320 (2014).
6. Wilkie, M. E. & McShane, H. TB vaccine development: where are we and why is it so difficult? Thorax 70, 299-301 (2015).
7. Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebocontrolled phase 2b trial. Lancet 381, 1021-1028 (2013).
8. McShane, H. et al. BCG: myths, realities, and the need for alternative vaccine strategies. Tuberculosis (Edinb) 92, 283-288 (2012).
9. Aronson, N. E. et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 291, 2086-2091 (2004).
10. Henao-Tamayo, M., Ordway, D. J. & Orme, I. M. Memory T cell subsets in tuberculosis: what should we be targeting? Tuberculosis (Edinb) 94, 455-461 (2014).
11. Garcia-Contreras, L. et al. Immunization by a bacterial aerosol. Proc. Natl Acad. Sci. USA 105, 4656-4660 (2008).
12. Barclay, W. R. et al. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107, 351-358 (1973).
13. Manjaly Thomas, Z. R. & McShane, H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans. R Soc. Trop. Med. Hyg. 109, 175-181 (2015).
14. Darrah, P. A. et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J. Immunol. 193, 1799-1811 (2014).
15. Larsen, M. H. et al. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27, 4709-4717 (2009).
16. Russell, D. G. The evolutionary pressures that have molded Mycobacterium tuberculosis into an infectious adjuvant. Curr. Opin. Microbiol. 16, 78-84 (2013).
17. Hmama, Z., Pena-Diaz, S., Joseph, S. & Av-Gay, Y. Immunoevasion and immunosuppression of the macrophage by Mycobacterium tuberculosis. Immunol. Rev. 264, 220-232 (2015).
18. Kaushal, D. et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc. Natl Acad. Sci. USA 99, 8330-8335 (2002).
19. Hernandez Pando, R., Aguilar, L. D., Smith, I. & Manganelli, R. Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infect. Immun. 78, 3168-3176 (2010).
20. Mehra, S. et al. The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. J. Infect. Dis. 205, 1203-1213 (2012).
21. Manganelli, R. et al. Role of the extracytoplasmic-function sigma factor sigma(H) in Mycobacterium tuberculosis global gene expression. Mol. Microbiol. 45, 365-374 (2002).
22. Dutta, N. K. et al. The stress-response factor SigH modulates the interaction between Mycobacterium tuberculosis and host phagocytes. PLoS ONE 7, e28958 (2012).
23. Barclay, W. R., Anacker, R. L., Brehmer, W., Leif, W. & Ribi, E. Aerosol-induced tuberculosis in subhuman primates and the course of the disease after intravenous BCG vaccination. Infect. Immun. 2, 574-582 (1970).
24. Mehra, S. et al. Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis. J. Infect. Dis. 207, 1115-1127 (2013).
25. Mehra, S. et al. The DosR regulon modulates adaptive immunity and is essential for M. tuberculosis persistence. Am. J. Respir. Crit. Care Med. 191, 1185-1196 (2015).
26. Kaushal, D., Mehra, S., Didier, P. J. & Lackner, A. A. The non-human primate model of tuberculosis. J. Med. Primatol. 41, 191-201 (2012).
27. Sharpe, S. A. et al. Determination of lesion volume by MRI and stereology in a macaque model of tuberculosis. Tuberculosis (Edinb) 89, 405-416 (2009).
28. Diedrich, C. R. et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS ONE 5, e9611 (2010).
29. Mehra, S. et al. Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus. J. Med. Primatol. 40, 233-243 (2011).
30. Kamath, A. T. et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23, 3753-3761 (2005).
31. Slight, S. R. et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J. Clin. Invest. 123, 712-726 (2013).
32. Dutta, N. K. et al. Genetic requirements for the survival of tubercle bacilli in primates. J. Infect. Dis. 201, 1743-1752 (2010).
33. Phillips, B. L. et al. LAG3 expression in active Mycobacterium tuberculosis infections. Am. J. Pathol. 185, 820-833 (2015).
34. Jayaraman, P. et al. IL-1beta promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J. Immunol. 190, 4196-4204 (2013).
35. Manca, C. et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J. Interferon Cytokine Res. 25, 694-701 (2005).
36. Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99-103 (2014).
37. Pitcher, C. J. et al. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168, 29-43 (2002).
38. Moyron-Quiroz, J. E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10, 927-934 (2004).
39. Fairfax, K. C. et al. IL-4-secreting secondary T follicular helper (Tfh) cells arise from memory T cells, not persisting Tfh cells, through a B cell-dependent mechanism. J. Immunol. 194, 2999-3010 (2015).
40. Phuah, J. Y., Mattila, J. T., Lin, P. L. & Flynn, J. L. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am. J. Pathol. 181, 508-514 (2012).
41. Nunes-Alves, C. et al. In search of a new paradigm for protective immunity to TB. Nat. Rev. Microbiol. 12, 289-299 (2014).
42. Kohlmeier, J. E. et al. Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J. Exp. Med. 208, 1621-1634 (2011).
43. Caruso, A. M. et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J. Immunol. 162, 5407-5416 (1999).
44. Chen, C. Y. et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 5, e1000392 (2009).
45. Mehra, S. & Kaushal, D. Functional genomics reveals extended roles of the Mycobacterium tuberculosis stress response factor sigmaH. J. Bacteriol. 191, 3965-3980 (2009).
46. Mehra, S., Dutta, N. K., Mollenkopf, H. J. & Kaushal, D. Mycobacterium tuberculosis MT2816 encodes a key stress-response regulator. J. Infect. Dis. 202, 943-953 (2010).
47. Kernodle, D. S. SigH, antioxidants, and the pathogenesis of pulmonary tuberculosis. J. Infect. Dis. 205, 1186-1188 (2012).
48. Winau, F., Hegasy, G., Kaufmann, S. H. & Schaible, U. E. No life without death - apoptosis as prerequisite for T cell activation. Apoptosis 10, 707-715 (2005).
49. Obst, R. et al. Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proc. Natl Acad. Sci. USA 104, 15460-15465 (2007).
50. Harris, J. & Keane, J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161, 1-9 (2010).
51. Wajant, H., Pfizenmaier, K. & Scheurich, P. Tumor necrosis factor signaling. Cell. Death Differ. 10, 45-65 (2003).
52. Bruns, H. et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest. 119, 1167-1177 (2009).
53. Harris, J., Hope, J. C. & Keane, J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J. Infect. Dis. 198, 1842-1850 (2008).
54. Schaible, U. E., Sturgill-Koszycki, S., Schlesinger, P. H. & Russell, D. G. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J. Immunol. 160, 1290-1296 (1998).
55. Kernodle, D. S. Decrease in the effectiveness of Bacille Calmette-Guerin vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overattenuation. Clin. Infect. Dis. 51, 177-184 (2010).
56. Novikov, A. et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J. Immunol. 187, 2540-2547 (2011).
57. Adekambi, T. et al. Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS ONE 7, e36046 (2012).
58. Riou, C. et al. A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion. PLoS ONE 9, e102178 (2014).
59. Hamilton, S. E. & Jameson, S. C. CD8 T cell memory: it takes all kinds. Front. Immunol. 3, 353 (2012).
60. Lin, P. L. et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 122, 303-314 (2012).
61. Ottenhoff, T. H. & Kaufmann, S. H. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 8, e1002607 (2012).
62. Cruz, A. et al. BCG vaccination-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4(+)IL-17(+)TNF(+)IL-2(+) T cells. Vaccine 33, 85-91 (2015).
63. Hartings, J. M. & Roy, C. J. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J. Pharmacol. Toxicol. Methods 49, 39-55 (2004).
64. Roy, C. J. et al. Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: epitope-specific neutralizing antibodies correlate with protection. Proc. Natl Acad. Sci. USA 112, 3782-3787 (2015).
65. Swearengen, J. R. Biodefense: Research Methodology and Animal Models 2nd edn (Taylor & Francis, 2012).
66. Darrah, P. A. et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J. Immunol. 193, 1799-1811 (2014).
67. Dutta, N. K., McLachlan, J., Mehra, S. & Kaushal, D. Humoral and lung immune responses to Mycobacterium tuberculosis infection in a primate model of protection. Trials Vaccinol. 3, 47-51 (2014).
68. Mehra, S. et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS ONE 5, e12266 (2010).
69. Gopal, R. et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am. J. Respir. Crit. Care Med. 188, 1137-1146 (2013).
70. Veazey, R. S. et al. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J. Virol. 74, 11001-11007 (2000).